![]() ![]() Added a brief statement about monkeypox with a link to information from the Centers for Disease Control and Prevention (CDC). ![]() Recommended the recombinant herpes zoster vaccine (RZV) for all individuals with HIV who are 18 years and older rather than 50 years and older.Noted that two new pneumococcal conjugate vaccines are now preferred for protection against invasive pneumococcal disease: PCV15 (given in series with PPSV23) and PCV20 (given as a single vaccine).Harmonized recommendations for the hepatitis B vaccine with the updated Hepatitis B Virus section (see above).Emphasized avoidance of dolutegravir/lamivudine (3TC) for antiretroviral therapy for people who are HBsAg positive because 3TC is the only active drug against hepatitis B virus in this regimen.Updated the information on vaccines to recommend a double-dose recombinant hepatitis B vaccine and to include as an alternative the recombinant HBsAg vaccine conjugated to CpG 1018 (Heplisav-B).Added links to useful government and professional association websites.Added a table of drug interactions between common antiretroviral and recommended HCV treatment regimens.Provided treatment regimens with an updated recommendation for the use of simplified, pan-genotypic regimens.Added criteria to identify patients who are eligible for a simplified hepatitis C virus (HCV) treatment approach.Major revisions within the last six months are as follows: JanuHepatitis C Virus ![]() (Changes in group composition also are posted promptly.) These changes are reviewed by the editors and by relevant outside reviewers before the document is altered. Conversely, patients with ACR <30 mg/g are generally are at lower risk and guidelines recommend the usual blood pressure (<140/90 mm Hg) using any antihypertensive medication.The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV document is published in an electronic format and updated as relevant changes in prevention and treatment recommendations occur.Īll changes are developed by the subject-matter groups listed in the document. Patients with ACR >30 mg/g have increased risk for all outcomes mentioned above, and current guidelines recommend lower blood pressure targets (<130/80 mm Hg) using an ACE inhibitor or ARB. "CKD is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health," and requires one of two criteria documented or inferred for >3 months: either GFR 300 mg/g, corresponding to what was previously referred to normoalbuminuria, microalbuminuria and macroalbuminuria (these terms are no longer used). In these paragraphs, we'll summarize what's new and not new about the definition and classification of CKD. Specifically, the guideline retains the definition of CKD but presents an enhanced classification framework for CKD elaborates on the identification and prognosis of CKD discusses the management of progression and complications of CKD and expands on the continuum of CKD care: timing of specialist referral, ongoing management of people with progressive CKD, timing of the initiation of dialysis, and finally the implementation of a treatment program which includes comprehensive conservative management." This was an ambitious undertaking for KDIGO and has broad implications for clinical practice. The rationale for the guideline update was "to provide state-of-the-art guidance on the evaluation, management and treatment for all patients with CKD. KDIGO has recently released a new CKD practice guideline, updating the 2002 NKF-KDOQI guideline. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |